Paolo Doretto

Dr. Paolo Doretto

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2024 in American Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
CPChiara Pratesi
Chiara Pratesi
RRRita De Rosa
Rita De Rosa
EPEliana Pivetta
Eliana Pivetta
KVKathreena Vattamattathil
Kathreena Vattamattathil
GMGiacomo Malipiero
Giacomo Malipiero
Paolo DorettoPaolo Doretto
Paolo Doretto
Acute infectious diseases are some of the most common reasons for receiving medical care, and analysis of the host immune response is an attractive approach for their diagnosis. The present study aimed to evaluate the potential usefulness of CD169 expression on peripheral monocytes (mCD169) as a marker of viral-associated host immune response. In a large mono-institutional cohort of 4,025 patients evaluated for SARS-CoV-2 (CoV2) and other viral infections, mCD169 analysis was performed by rapid flow cytometry assay. Increased mCD169 values (median, 17.50; IQR, 8.40-25.72) were found in 1,631 patients with CoV2+ acute infection compared to 2,394 in CoV2– patients (median, 2.35; IQR, 2.0-3.25) (odds ratio [OR], 21.84; 95% CI ,17.53-27.21; P < .001). Among CoV2– patients, 1,484 (62.0%) were assessed for other viral infections, and viral etiology was laboratory confirmed in 428 patients (CoV2– Vir+), with RNA viruses most frequently detected (94.6%). Higher levels of mCD169 were also confirmed in CoV2– Vir+ compared to CoV2– Vir– patients (OR, 10.05; 95% CI, 7.35-13.74; P < .001). mCD169 analysis by rapid flow cytometry assay may be a sensitive broad marker useful for the rapid triage of patients with suspected acute viral infections and could potentially be directly applied to eventual new emergent viral outbreaks.

16 January 2025 in Infection
Verified
Journal Article
Closed access
PDF file
SVsergio venturini
sergio venturini
MCMassimo Crapis
Massimo Crapis
AZAgnese Zanus-Fortes
Agnese Zanus-Fortes
DODaniele Orso
Daniele Orso
FCFrancesco Cugini
Francesco Cugini
Carlo TasciniCarlo Tascini
Carlo Tascini

30 July 2024 in Hemato
Verified
Journal Article
Open access
PDF file
GMGiacomo Malipiero
Giacomo Malipiero
AEAnna Ermacora
Anna Ermacora
CPChiara Pratesi
Chiara Pratesi
Antonino CarboneAntonino Carbone
Antonino Carbone
ARAdolfo Rogato
Adolfo Rogato
Paolo DorettoPaolo Doretto
Paolo Doretto
Refractoriness to standard first-line therapy in immune thrombocytopenia (ITP) should foster additional diagnostic work-up to exclude hematological clonal disease, mostly myelodysplatic syndrome (MDS) or clonal cytopenia of unknown significance (CCUS), which may present with isolated thrombocytopenia of immune or non-immune origin. We herein report on a patient who showed a transient leukoerythroblastic reaction (LEB) associated with bone marrow myelofibrosis upon rompilostim treatment, challenging a diagnosis of primary ITP and requiring additional investigations. RUNX-1-mutated myelodysplastic syndrome was eventually diagnosed. Even though LEB and marrow fibrosis have already been rarely reported during romiplostim treatment for ITP, this is the first case to our knowledge in which a background clonal hematopoiesis was diagnosed and deemed potentially involved in the abnormal response to this thrombopoietin receptor agonist (TPO-RA).

15 September 2023 in Hemato
Verified
Journal Article
Open access
PDF file
GMGiacomo Malipiero
Giacomo Malipiero
PMPiernicola Machin
Piernicola Machin
AEAnna Ermacora
Anna Ermacora
CPChiara Pratesi
Chiara Pratesi
Antonino CarboneAntonino Carbone
Antonino Carbone
Paolo DorettoPaolo Doretto
Paolo Doretto
Kikuchi–Fujimoto disease (KFD) is a rare, benign lymphoproliferative disease of uncertain origin that can mimic other inflammatory or clonal lymphoproliferative disorders. Given the lack of available blood biomarkers, diagnosis is based on the biopsy of an affected lymph node. In recent years, evidence has been mounting that a dysregulated type I INF innate immune response plays a pivotal role in the pathogenesis of the disease and might be a future therapeutic target. Nonetheless, laboratory assays measuring the expression of interferon alpha (INFα) and INF-stimulated genes (ISGs) are cumbersome and not widely available, limiting their use in clinical and translational research and encouraging the use of more convenient surrogate markers. In this study, a rapid flow cytometry assay detected increased levels of expression of CD169 (Siglec-1), an INFα-induced surface protein involved in innate immunity regulation, on circulating monocytes from two patients with KFD. Our results are in line with previous experiences and set the stage for a more extended investigation into the use of this assay in exploring the pathophysiology of KFD.